Answer
Concomitant isavuconazole increases exposure (AUC) to mycophenolic acid (MPA), the active metabolite of mycophenolate mofetil hydrochloride (CellCept), by 35%.
Sources for this answer
- Cellcept 500mg powder for concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 39Document updated
Sources checked